Not playing NICE: UK drugs gatekeeper in US crosshairs

“They propose … an agreement by both parties to recognize a variety of value criteria; and that [health technology assessment] should not be the principle framework for assessing value,” said Sam Lowe, senior research fellow at the Centre for European Reform.

...“If I were to be a betting man, I would say that the US would need to drop [drug pricing] as a substantive ask in order to get a deal over the line … maybe … because however impactful or not measures would be is sort of irrelevant in that it just won’t pass muster with the British public,” said Lowe.